SCHEMBL29894136

SCHEMBL29894136

Cn1c(C=O)cc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51
GRIN3A Q8TCU5 1/20 0.51
DAO P14920 1/20 0.50
MCL1 Q07820 1/20 0.50
KMT2A Q03164 2/20 0.48
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
BRD4 O60885 1/20 0.47
BRPF1 P55201 1/20 0.47
KAT2B Q92831 1/20 0.47
BRD9 Q9H8M2 1/20 0.47
ABCC2 Q92887 1/20 0.44
ALB P02768 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342762 1.00 GRIN2D (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL21803732 0.82 GRIN2D (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5640746 0.82 GRIN2D (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2898725 0.80 GRIN2D (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7971398 0.80 GRIN2D (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3190799 0.79 KMT2A (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27786799 0.78 GRIN2D (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15720744 0.78 POLB (0.42) KMT2ABRD4ABCC2ALDH1A1MAPT
SCHEMBL7968178 0.78 MCL1 (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4589923 0.78 CYP2A6 (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353863-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY INST NAT SANTE RECH MED (FR) 2025-11-20 US disclosed
CN-115772114-B Method for synthesizing 2, 3-dihydropyridinone by one-pot catalysis of iodopyridinium salt 成都理工大学 2024-09-06 CN disclosed
US-11427596-B2 Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications Indian Institute of Technology Indore (IN) 2022-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11427596-B2 Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications SLC11A2, WEE1, BRCA1 GRIN2D 3014/4885GRIN3B 3552/4885GRIN1 3033/4885
US-20250353863-A1 TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY TALDO1, TBCA, TBCD GRIN2D 4808/4885GRIN3B 4836/4885GRIN1 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.